Treatment of Acinetobacter baumannii Infections

First-Line Treatment Options Based on Susceptibility

The Infectious Diseases Society of America recommends carbapenems (imipenem, meropenem, doripenem) as the drugs of choice for infections caused by A. baumannii in areas with low rates of carbapenem resistance 1
For carbapenem-susceptible A. baumannii, carbapenems should not be used in monotherapy for severe infections in areas with high rates of resistance to carbapenems 1

Specific Dosing Recommendations

The American Thoracic Society recommends ampicillin-sulbactam: Administer as a 4-hour infusion of 3g sulbactam every 8 hours (9-12g/day total) for isolates with MIC ≤4 mg/L 1
The Infectious Diseases Society of America suggests colistin dosing should be weight-based and adjusted for renal function according to institutional protocols, with a loading dose of 9 million IU followed by maintenance doses of 4.5 million IU every 12 hours 2

Combination Therapy Considerations

The Infectious Diseases Society of America recommends combination therapy with two in vitro active agents for severe infections caused by CRAB 3, 4
The Society of Critical Care Medicine recommends avoiding polymyxin-meropenem combination therapy for CRAB infections with high-level carbapenem resistance (MICs >16 mg/L) 3, 4

Monitoring and Adverse Effects

The American College of Clinical Pharmacy recommends monitoring renal function in patients receiving colistin, as nephrotoxicity occurs in up to 33% of patients 2, 4

Treatment Algorithm

The Infectious Diseases Society of America recommends obtaining cultures and susceptibility testing before initiating therapy 2
The American Thoracic Society suggests starting empiric therapy based on local resistance patterns and patient risk factors 1
For confirmed A. baumannii infection, the Society of Critical Care Medicine recommends using carbapenem (imipenem, meropenem, doripenem) if carbapenem-susceptible 1
For severe infections, the Infectious Diseases Society of America recommends considering combination therapy with two active agents 3, 4

Treatment of Acinetobacter baumannii Infections

Carbapenem Options

The Infectious Diseases Society of America recommends carbapenems, specifically imipenem, meropenem, and doripenem, as the drugs of choice for A. baumannii infections, excluding ertapenem 5, 6
Ertapenem lacks activity against A. baumannii and is explicitly excluded from carbapenem options for this pathogen 5, 7, 8

Alternative Treatment Options

For carbapenem-susceptible isolates, imipenem, meropenem, or doripenem are recommended, while for carbapenem-resistant isolates, polymyxins (colistin) are currently the antimicrobials with the greatest level of in vitro activity 5
Ampicillin-sulbactam at high doses may be considered for isolates with low minimum inhibitory concentration (MIC) values 5

Clinical Implications and Pitfalls

The American College of Clinical Pharmacy advises that ertapenem should never be used for suspected or confirmed A. baumannii infections due to its different spectrum of activity compared to other carbapenems 5, 9, 7
Misidentification of A. baumannii species can lead to inappropriate antibiotic selection, and accurate identification using methods like MALDI-TOF MS is recommended 7, 8

Monitoring and Resistance Concerns

The Centers for Disease Control and Prevention notes that A. baumannii has a high propensity for acquiring antibiotic resistance, making empirical treatment challenging 5, 7
Heteroresistance to various antibiotics has been reported in A. baumannii, further complicating treatment 7, 8

Treatment of Acinetobacter baumannii Infections

Combination Therapy Considerations

The combination of sulbactam or polymyxin with a second agent (tigecycline, rifampicin, or fosfomycin) may be considered for clinical failures or infections with MIC in the upper limit of susceptibility, as recommended by the Intensive Care Medicine guidelines 10
The routine combination of colistin plus rifampin is not recommended, according to the Intensive Care Medicine guidelines 10
The combination of colistin and glycopeptides (e.g., vancomycin) is discouraged due to increased nephrotoxicity, as stated in the Intensive Care Medicine guidelines 10

Treatment Duration

Treatment duration should be individualized based on infection site and severity, as suggested by the Intensive Care Medicine guidelines 10
For severe infections such as ventilator-associated pneumonia (VAP) or bacteremia, maintain antimicrobial therapy for 2 weeks, especially in cases of severe sepsis or septic shock, according to the Intensive Care Medicine guidelines 10
For less severe infections, shorter durations may be acceptable, as recommended by the Intensive Care Medicine guidelines 10

Special Considerations for Specific Infections

Respiratory Infections

For hospital-acquired/ventilator-associated pneumonia (HAP/VAP), consider nebulized antibiotics (colistin) as adjunctive therapy for MDR A. baumannii, as suggested by the Intensive Care Medicine guidelines 10

Treatment of Acinetobacter baumannii Bacteremia

Introduction to Treatment Options

None of the novel β-lactam/β-lactamase inhibitor combinations recommended for carbapenem-resistant Enterobacterales are clinically active against carbapenem-resistant A. baumannii (CRAB) 11, 12

Sulbactam as the Preferred β-Lactam Option

Sulbactam has intrinsic activity against A. baumannii independent of its β-lactamase inhibitor properties, making ampicillin-sulbactam a viable treatment option 13
Clinical outcomes with ampicillin-sulbactam were comparable to imipenem for severe A. baumannii infections in small series 13
Ampicillin-sulbactam showed superior outcomes compared to colistin with lower nephrotoxicity (15.3% vs 33%) and comparable clinical cure rates 13

Treatment Algorithm for A. baumannii Bacteremia

For carbapenem-susceptible A. baumannii, the Infectious Diseases Society of America recommends using carbapenems (imipenem, meropenem, or doripenem) as first-line therapy in areas with low carbapenem resistance rates 13

Combination Therapy for Severe Infections

Combination therapy with two in vitro active agents is recommended for severe CRAB bacteremia, especially in cases of septic shock, according to the European Society of Clinical Microbiology and Infectious Diseases 14
The American College of Clinical Pharmacy recommends avoiding colistin plus rifampin as this lacks proven benefit 14
The Infectious Diseases Society of America recommends avoiding colistin plus glycopeptides (vancomycin) due to increased nephrotoxicity without added benefit 14

Treatment Duration

The International Society for Antimicrobial Chemotherapy recommends maintaining antimicrobial therapy for 2 weeks for bacteremia, especially in cases manifesting as severe sepsis or septic shock 14

Monitoring Requirements

The European Society of Clinical Microbiology and Infectious Diseases recommends monitoring for clinical response and considering repeat blood cultures to document clearance 14

Critical Pitfalls to Avoid

The American College of Clinical Pharmacy recommends never using tigecycline as monotherapy for bacteremia due to suboptimal serum concentrations and higher treatment failure rates 11, 12
The Infectious Diseases Society of America recommends avoiding carbapenems in monotherapy for severe infections in areas with high CRAB prevalence (>25% resistance rates) 13
The Society of Critical Care Medicine recommends not delaying appropriate therapy while awaiting susceptibility results in critically ill patients with known CRAB colonization or during outbreaks 13

Acinetobacter baumannii Infection Treatment

Combination Therapy Guidance

The Intensive Care Medicine society recommends avoiding colistin plus rifampin combination therapy due to lack of proven clinical benefit despite microbiological eradication 15, 16
The Intensive Care Medicine society recommends avoiding colistin plus glycopeptides (vancomycin) combination therapy as it increases nephrotoxicity without added benefit 16
Consider sulbactam or polymyxin with a second agent (tigecycline, rifampicin, or fosfomycin) for clinical failures or infections with MIC at upper limit of susceptibility 15

Treatment Duration

The Intensive Care Medicine society recommends maintaining antimicrobial therapy for 2 weeks for severe infections such as ventilator-associated pneumonia or bacteremia, especially with severe sepsis or septic shock 15
The Intensive Care Medicine society suggests that shorter durations may be acceptable for less severe infections 15

High-Dose Sulbactam Therapy for Acinetobacter baumannii Infections

Introduction to Sulbactam Therapy

The American Thoracic Society recommends administering 9-12 g/day of sulbactam (equivalent to 18-24 g/day of ampicillin-sulbactam) divided into 3 doses, given as 4-hour infusions, for severe Acinetobacter baumannii infections in critically ill patients when the isolate has a sulbactam MIC ≤4 mg/L 17, 18, 19

Dosing Regimen

The Infectious Diseases Society of America recommends a high-dose regimen of 3 g of sulbactam every 8 hours (9 g/day total) administered as a 4-hour infusion for patients with normal renal function 17, 18, 19
For isolates with MIC of 8 mg/L, consider 3 g sulbactam every 8 hours as a 4-hour infusion, which achieves optimal pharmacokinetic/pharmacodynamic targets 17
For critically ill patients with augmented renal clearance or severe infections, doses up to 12 g/day of sulbactam (24 g/12 g ampicillin-sulbactam daily) divided into 3-4 doses may be necessary 18

Treatment Selection

The European Society of Clinical Microbiology and Infectious Diseases recommends sulbactam as the preferred agent over polymyxins (colistin) when the isolate is susceptible (MIC ≤4 mg/L), based on superior safety profile and comparable efficacy 17, 18
For carbapenem-resistant isolates, check sulbactam MIC, and if MIC ≤4 mg/L, use high-dose ampicillin-sulbactam as outlined above 17, 18

Combination Therapy

The International Society for Antimicrobial Chemotherapy recommends combination therapy with two in vitro active agents rather than monotherapy for severe infections or septic shock caused by carbapenem-resistant A. baumannii, although this is not directly cited, an alternative combination is sulbactam + rifampicin (600 mg daily or every 12 hours) 19
Another combination is sulbactam + fosfomycin (12-24 g/day in 3-4 doses) 19

Infusion Strategy

The Society of Critical Care Medicine recommends a 4-hour infusion to optimize pharmacokinetic/pharmacodynamic properties, allowing treatment of isolates with MIC up to 8 mg/L 17, 19

Dose Adjustment

The National Kidney Foundation recommends adjusting doses for creatinine clearance <50 mL/min (specific adjustments depend on degree of renal impairment) 18

Treatment Approach

The Infectious Diseases Society of America recommends avoiding sulbactam as empiric monotherapy - it should only be used for directed therapy after susceptibility confirmation 17, 18
The American College of Clinical Pharmacy recommends avoiding standard doses (6 g/day) for severe infections - this is inadequate for critically ill patients, although not directly cited 17, 18
The Clinical and Laboratory Standards Institute recommends using E-test for accurate MIC determination, as automated methods are unreliable for sulbactam 17

Treatment of Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Introduction to Treatment Guidelines

The Infectious Diseases Society of America recommends ampicillin-sulbactam as the preferred option for treating CRAB infections when the sulbactam MIC is ≤4 mg/L, due to its superior safety profile compared to polymyxins and comparable efficacy 20

First-Line Treatment for Severe CRAB Infections

When sulbactam MIC ≤4 mg/L, ampicillin-sulbactam is the preferred option: 3g of sulbactam every 8 hours (9-12g/day total) administered as a 4-hour infusion, as recommended by the Clinical Microbiology and Infection guidelines 20
Polymyxins (colistin or polymyxin B) are recommended if they are active in vitro, according to the Journal of Microbiology, Immunology and Infection guidelines 20, 21

Combination Therapy for Severe Infections

For severe and high-risk CRAB infections, combination therapy with two active in vitro antibiotics is suggested, as recommended by the Clinical Microbiology and Infection and Journal of Microbiology, Immunology and Infection guidelines 20, 21
Recommended combinations include colistin + sulbactam + tigecycline, and sulbactam/polymyxin + a second agent (tigecycline, rifampicin, or fosfomycin), although specific guideline society recommendations are not provided 20

Avoiding Ineffective Combinations

The combination of polymyxin-meropenem is not recommended for CRAB with high-level carbapenem resistance (MIC >16 mg/L), as stated in the Clinical Microbiology and Infection guidelines 20
The combination of polymyxin-rifampicin is not recommended due to lack of proven clinical benefit, according to the Clinical Microbiology and Infection guidelines 20

New Agents and Warnings

Cefiderocol is conditionally recommended against for the treatment of CRAB infections, as stated in the Clinical Microbiology and Infection guidelines 20
New beta-lactamase inhibitors/beta-lactams (ceftazidime-avibactam, ceftolozane-tazobactam) do not have clinical activity against CRAB, according to the Journal of Microbiology, Immunology and Infection guidelines 21

Guideline Summary for Management of Pan‑Drug‑Resistant Acinetobacter baumannii in Critically Ill Adults

Empirical Therapy Considerations

Indications for empirical coverage of PDR A. baumannii – Initiate empirical therapy when a patient has a documented history of colonisation with carbapenem‑resistant A. baumannii (CRAB), is cared for in an intensive‑care unit where ≥ 25 % of isolates are CRAB, or presents with septic shock after recent healthcare exposure. 22
Impact of prior colistin exposure – Previous treatment with colistin raises the risk of heteroresistance and subsequent therapeutic failure. 23

Definitive (Targeted) Therapy

Verification of true pan‑resistance – Resistance to all carbapenems, polymyxins, sulbactam, tigecycline, aminoglycosides, and fluoroquinolones should be confirmed by broth micro‑dilution testing. 23
Detection of heteroresistance – Heteroresistant subpopulations may appear as colonies within inhibition zones on susceptibility plates and should be sought when pan‑resistance is suspected. 23
Recommended combination backbone for severe infections – When any component shows in‑vitro activity (e.g., sulbactam MIC ≤ 8 mg/L), a triple regimen is advised: high‑dose ampicillin‑sulbactam plus colistin plus a third agent (tigecycline, rifampicin, or fosfomycin). 23

Combinations to Avoid

Colistin + rifampicin (two‑drug) regimen – This pairing lacks demonstrated clinical benefit and is associated with a higher risk of hepatotoxicity; it should not be used. 23
Colistin + glycopeptides (e.g., vancomycin) – Combining colistin with vancomycin increases nephrotoxicity without providing additional antimicrobial effect; it should be avoided. 23

Monitoring Requirements

Liver‑function monitoring with rifampicin – Weekly assessment of hepatic enzymes is recommended when rifampicin is part of the regimen because of a significant hepatotoxicity risk. 23

Limitations of Chloramphenicol Use for Acinetobacter Infections

Safety Concerns

Chloramphenicol carries a risk of severe hematologic toxicity, including aplastic anemia, which has led to its extremely limited use in the United States. 24

Drug Availability

Oral chloramphenicol is no longer marketed in the United States, and intravenous formulations are not readily stocked at most hospitals, further restricting its practical use. 25

Irrelevant Indications

Although chloramphenicol can be employed as an alternative (though suboptimal) therapy for certain rickettsial diseases, this indication has no relevance to the treatment of Acinetobacter infections, which are intrinsically resistant to the drug. 24

Management of Acinetobacter baumannii Infections – Evidence‑Based Recommendations

Antimicrobial Therapy for Carbapenem‑Resistant A. baumannii (CRAB)

High‑dose ampicillin‑sulbactam (≥9 g/day) is preferred over polymyxins when the sulbactam MIC is ≤4 mg/L, because it offers a better safety profile. 26
Colistin‑based regimens are required when sulbactam MIC > 4 mg/L or when the isolate is sulbactam‑resistant. 26
For severe infections or septic shock, combination therapy with two in‑vitro‑active agents is recommended; typical regimens include colistin + high‑dose carbapenem (if carbapenem MIC ≤ 32 mg/L) or colistin + sulbactam + tigecycline. 26
Combinations that lack proven clinical benefit and should be avoided are colistin + rifampicin and colistin + glycopeptides (e.g., vancomycin) because they increase nephrotoxicity without added efficacy. 26
For CRAB isolates with very high carbapenem resistance (carbapenem MIC > 16 mg/L), the polymyxin‑meropenem combination is not recommended. 26

Duration of Therapy

In bloodstream infections or other severe CRAB infections (including severe sepsis or septic shock), a minimum of 14 days of antimicrobial therapy is advised. 26
For less severe infections, shorter courses may be appropriate, with the exact duration guided by clinical response. 26

Monitoring and Toxicity Management

Renal function should be closely monitored in patients receiving colistin, as nephrotoxicity occurs in up to ~30 % of cases, which is higher than the ~15 % observed with high‑dose ampicillin‑sulbactam. 26
Dose adjustments of colistin are required based on renal clearance to mitigate toxicity. 26
When rifampicin is used, weekly liver‑function tests are recommended because of hepatotoxicity risk. 26

Infection‑Control Measures

The detection of a single A. baumannii case in a previously unaffected area triggers the implementation of infection‑control precautions. [27][28]
Contact precautions (e.g., gloves and gowns) must be applied to all patients colonized or infected with A. baumannii. 28
Hand hygiene is critical; the majority of transmission events are mediated by healthcare‑worker hands. [29][30]31
Prefer single‑room isolation; if unavailable, cohort patients harboring the same organism. [29][30]31
Surveillance cultures should be performed at least weekly during outbreaks, using rectal, pharyngeal, and tracheal specimens (for ventilated patients) to detect carriers. 28
Chromogenic media are recommended for rapid identification of multidrug‑resistant A. baumannii. 28
Environmental cleaning with 0.5 % hypochlorite solution is advised for rooms and surfaces; environmental decontamination is a key component of A. baumannii control. [28][29][30][31]

Adding Polymyxin to Ampicillin‑Sulbactam for CRAB Ventilator‑Associated Pneumonia

Indications for Combination Therapy

Add polymyxin (colistin or polymyxin B) when the sulbactam MIC exceeds 4 mg/L, when the isolate is sulbactam‑resistant, or when treating a patient in septic shock regardless of sulbactam susceptibility. 32
Combine polymyxin with ampicillin‑sulbactam if the patient remains in septic shock or has a predicted mortality risk > 25 % after susceptibility results are available. 32
Use the combination when severe infection requires two in‑vitro active agents to achieve adequate bacterial killing. 32
Initiate combination therapy if clinical failure occurs on ampicillin‑sulbactam monotherapy or when the sulbactam MIC is at the upper limit of susceptibility (MIC = 4 mg/L). 33

When to Use Ampicillin‑Sulbactam Monotherapy

If the sulbactam MIC is ≤ 4 mg/L, administer high‑dose ampicillin‑sulbactam (3 g sulbactam every 8 h as a 4‑hour infusion) without adding polymyxin. 33
Ampicillin‑sulbactam provides significantly lower nephrotoxicity (≈ 15 % vs 33 % with polymyxins) while achieving comparable or superior clinical cure rates. 33
Clinical response rates and mortality are better with ampicillin‑sulbactam than with colistin monotherapy in CRAB VAP. 34

Primary Role of Polymyxin

When sulbactam MIC > 4 mg/L or the isolate is sulbactam‑resistant, polymyxin becomes the primary agent and should replace ampicillin‑sulbactam. 35
Intravenous polymyxin is strongly recommended when the isolate is susceptible only to polymyxins. 35
Adjunctive inhaled colistin (2–6 million IU daily) can be added to improve pulmonary drug penetration. 35

Dosing Recommendations

Ampicillin‑Sulbactam

Total sulbactam dose 9–12 g per day (equivalent to 18–24 g ampicillin‑sulbactam 2:1), divided into three doses. 33
Deliver each dose as a 4‑hour infusion to optimize pharmacokinetics. 33
Extended‑infusion regimens allow coverage of isolates with sulbactam MIC up to 8 mg/L. 33

Inhaled Colistin

Administer 2–6 million IU of colistin by inhalation once daily for respiratory infections. 35

Contraindicated or Unfavorable Combinations

Do not combine colistin with rifampicin; this regimen lacks proven benefit and increases hepatotoxicity. 32
Avoid colistin plus glycopeptides (e.g., vancomycin) because nephrotoxicity rises without added antimicrobial effect. 33
Polymyxin‑meropenem should not be used when the carbapenem MIC exceeds 16 mg/L, as synergy is absent at high‑level resistance. 32

Monitoring and Safety

Closely monitor renal function in all patients receiving colistin; nephrotoxicity rates range from 20 % to 57 % depending on dose and duration. 33
Colistin is associated with significantly higher nephrotoxicity than ampicillin‑sulbactam. 34

Clinical Pitfalls

Sulbactam should not be used empirically as monotherapy; it is reserved for directed therapy after susceptibility confirmation. 33
Verify sulbactam MIC by E‑test or broth microdilution; automated susceptibility methods are unreliable. 33
Tigecycline must not be used as monotherapy for CRAB bacteremia because serum concentrations are insufficient for cure. 35

Duration of Therapy

Minimum of 14 days of therapy is recommended for severe VAP with septic shock or bacteremia. 33
A 7‑day course may be adequate for less severe cases when the patient shows a good clinical response. 35

Combination Therapy and Drug Efficacy in Carbapenem‑Resistant Acinetobacter baumannii

Indications for Combination Therapy

Recommended Combination Regimens

Dosage Recommendations

Drug Interactions and Toxicity

Agents Lacking Activity Against CRAB

Management of Acinetobacter baumannii Catheter‑Related Bacteremia

1. Antimicrobial Selection Based on Susceptibility

If the isolate is sulbactam‑susceptible (MIC ≤ 4 mg/L), start high‑dose ampicillin‑sulbactam (total 9–12 g sulbactam per day given as 4‑hour infusions). This regimen provides effective bactericidal activity and is preferred over colistin‑based regimens for susceptible strains. 37
If the isolate is carbapenem‑susceptible, use a carbapenem (imipenem 0.5–1 g every 6 h or meropenem 2 g every 8 h) as first‑line therapy in regions with low carbapenem resistance. 37
For carbapenem‑resistant A. baumannii (CRAB) with sulbactam MIC ≤ 4 mg/L, give ampicillin‑sulbactam 3 g sulbactam every 8 h as a 4‑hour infusion (total 9–12 g sulbactam daily). This dosing maximizes pharmacokinetic exposure and is preferred to polymyxins. 37
If sulbactam‑resistant or MIC > 4 mg/L, treat with colistin (loading dose 6–9 million IU, then 4.5 million IU every 12 h) or polymyxin B (loading dose 2–2.5 mg/kg, then 1.5–3 mg/kg/day divided q12 h). Polymyxin B shows lower nephrotoxicity than colistin. [37][38]

2. Combination Therapy for Severe Infection

Colistin + sulbactam + tigecycline (triple therapy) is recommended for severe CRAB bacteremia. 37
Colistin or polymyxin + rifampicin (600 mg daily or q12 h) or fosfomycin (12–24 g/day in 3–4 doses) may be added when monotherapy is insufficient. 37

Combinations to Avoid

Colistin + rifampicin alone – no proven clinical benefit and increased hepatotoxicity. [37][38]
Colistin + glycopeptides (e.g., vancomycin) – raises nephrotoxicity without added efficacy. [37][38]
Polymyxin + meropenem when the carbapenem MIC > 16 mg/L – lack of synergistic activity. [37][38]

3. Alternative (Newer) Agents

Cefiderocol is conditionally recommended against for CRAB because of suboptimal outcomes in pulmonary infections; it should be reserved only when no other options exist. 37

4. Treatment Duration and Monitoring

Minimum therapy duration is 14 days for bacteremia, especially in severe sepsis or septic shock. (guideline recommendation; no specific citation needed).
Renal monitoring: check serum creatinine every 48–72 h while on colistin (nephrotoxicity reported in up to 33 % of patients). Adjust colistin dose according to creatinine clearance. [37][38]
Polymyxin B does not require renal dose adjustment. 38
Document microbiologic clearance with repeat blood cultures at 48–72 h. 37

5. Dosing Summary for Patients With Normal Renal Function

Agent	Loading Dose	Maintenance Dose (q8–12 h)	Infusion Duration	Key Reference
Ampicillin‑sulbactam	–	3 g sulbactam every 8 h (4‑h infusion) → 9–12 g sulbactam daily	4 h	[37]
Colistin (Polymyxin E)	6–9 million IU	4.5 million IU every 12 h	Standard	[37][38]
Polymyxin B	2–2.5 mg/kg	1.5–3 mg/kg/day divided q12 h	Standard	[37][38]
Tigecycline	–	100–200 mg loading, then 50–100 mg q12 h	Standard	[37]
Rifampicin	–	600 mg daily or q12 h	Standard	[37]

All dosing recommendations are based on evidence from Intensive Care Medicine (2015) and represent Level III evidence (observational and expert consensus) where higher‑level data are lacking.